56
Participants
Start Date
January 2, 2018
Primary Completion Date
July 11, 2022
Study Completion Date
May 29, 2023
losartan
taken orally
dextromethorphan
taken orally
caffeine
taken orally
omeprazole
taken orally
midazolam
taken orally
rosuvastatin
taken orally
bupropion immediate release (IR)
taken orally
encorafenib
taken orally
binimetinib
taken orally
modafinil
taken orally
Universitair Ziekenhuis Antwerpen, Edegem
Hospital Universitari Arnau de Vilanova, Lleida
Hospital Beata Maria Ana, Madrid
Hospital General Universitario Gregorio Marañon, Madrid
Clinica Rementeria, Madrid
MD Anderson Cancer Center Madrid, Madrid
Hospital Universitario HM Sanchinarro - CIOCC, Madrid
Hospital Clinico Universitario Virgen de la Arrixaca, El Palmar
University of TN Medical Center, Knoxville
CERCO, Seville
Hospital Universitario Virgen Macarena, Seville
Gabrail Cancer Center Research, Canton
Regions Cancer Care Center, Saint Paul
HealthPartners Specialty Center-Eye Care, Saint Paul
Park Nicollet Eye Clinic, Maple Grove
University of Illinois at Chicago, Chicago
Mary Crowley Cancer Research - Medical City Hospital, Dallas
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora
Utah Cancer Specialists, West Valley City
UC Irvine Health, Orange
Hopkins Eye Clinic, Hopkins
Cross Cancer Institute, Edmonton
Princess Margaret Cancer Centre, Toronto
Sir Mortimer B Davis Jewish General Hospital, Montreal
Jewish General Hospital, Montrea
McGill University Health Center, Montreal
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam
Erasmus Medical Center, Rotterdam
Hospital del Mar, Barcelona
Lead Sponsor
Collaborators (1)
Pierre Fabre Laboratories
INDUSTRY
Pfizer
INDUSTRY